ࡱ> q Kbjbjt+t+  AAC?]$NNNNP4N      3Q ] i $D8  > "` " <<. <88 "",""<<  b  t  C=QNN  ALASKA WORKERS' COMPENSATION BOARD PRIVATE  P.O. Box 25512 Juneau, Alaska 99802-5512 BUDDY H. NORTH, ) ) Employee, ) DECISION AND ORDER ) and ) AWCB Case No. 9619092 ) ALASKA PHYSICAL THERAPY & ) AWCB Decision No. 97-0182 REHABILITATION ) ) Filed with AWCB Anchroage Applicant, ) August 28, 1997 ) v. ) ) ANCHORAGE SCHOOL DISTRICT, ) (Self-Insured) ) Employer, ) Defendant. ) ___________________________________) On July 30, 1997, we heard Applicant's February 26, 1997 claim requesting payment for medical treatment provided to Employee which was billed at a higher rate than paid by Employer. Employee is not represented and did not appear at the hearing. Applicant's claim was presented by Mr. Raymond Schalow. Employer's defense was presented by Adjustor Carrie Kay. We closed the record at the end of the hearing. ISSUE Which, if any, American Medical Association (AMA) Physicians' Current Procedural Terminology (CPT) service code should be assigned to VAX-D Therapeutic Table (VAX-D) treatments for purposes of payment? SUMMARY OF THE EVIDENCE AND ARGUMENTS Employee injured his back on September 5, 1996 while working for Employer. (September 12, 1996 Report of Injury). In October 1996, Employee began VAX-D Therapeutic Table (VAX-D) treatments with Applicant. (Employee's October 14, 1996 VAX-D Initial Screening Form). Employer's adjustor, Carrie Kay, testified at hearing that she sent the bills for such treatments to CorVel Corporation (CorVel) to review for payment. Elizabeth Cline testified at hearing that she is the MedCheck Supervisor at CorVel and that she contacted the AMA coding department and inquired about which CPT service code should be assigned to VAX-D treatments. In response to her inquiry, the AMA Department of Coding and Nomenclature's June 3, 1996 letter (Employer's Hearing Exhibit 7) states: From a coding perspective, CPT code 97012, Application of a modality to one or more areas; traction, mechanical should be reported for the procedure performed on the VAX-D table. . . . . CPT code 64722 should not be reported for the VAX-D treatment as code 64722 represents an invasive procedure involving nerves. Ms. Kay testified that she paid Employee's VAX-D treatments at the rate of $40.78 each. We administratively note that $40.68 is the recommended payment for procedure code 97012, designated as "TRACTION-MECH". (Alaska Workers' Compensation Fee Schedule (Fee Schedule) at page 234). In addition to presenting Applicant's claim, Mr. Raymond Schalow testified at hearing. Mr. Schalow testified that he is the business manager for Applicant and that Applicant bills individual VAX-D treatments at $175.00. Mr. Schalow testified that Applicant is the only facility to offer VAX-D treatments in Alaska. Mr. Schalow further testified the VAX-D is a new modality which the Federal Drug Administration (FDA) certified as a "decompression device" on July 6, 1996. Mr. Schalow testified that in addition to being Applicant's business manager, he also serves as the national Treasurer for the VAX-D Technology Medical Association. He testified that, nationwide, VAX-D treatments are billed between $175 and $220 per treatment. Mr. Schalow further testified that Applicant has also billed VAX-D treatments at CPT code 64722, because the treatment results in a disc decompression. We administratively note that CPT code 64722 is described as "DECOMP; UNSPECIFIED NERVE (SPECIFY)" with a "total fee" of $1733.14 and is listed in the surgery section of the Fee Schedule. Id. at 157. Furthermore, on at least one occasion, Applicant has billed Employee's VAX-D treatment at $175.00 with CPT code 97799. (Employer's Hearing Exhibit 7; October 31, 1996 Insurance Claim Form). CPT code 97799 is described as "UNLISTED PHYS MEDS/REHAB SERV/PROC" with the "total fee" designated as "BR." Id. at 235. "BR indicates a 'By Report' procedure, which is typically one that is too variable to accept a set relative value." Id. at 5. Karen Ratliff, M.S., testified at hearing that she is a licensed physical therapist employed by Applicant. Ms. Ratliff testified that patients are assessed after every ten sessions to determine whether they should continue treatment, and assessed again when discharged. Ms. Ratliff testified that based on her professional experience, the results from VAX-D therapy are far superior to the results obtained from conventional traction therapy. Ross Brudenell, M.D., testified he is Applicant's medical director. Dr. Brudenell testified that he critically assesses potential VAX-D therapy patients to determine whether they are appropriate candidates for such treatment. He applies specific criteria to determine whether the source of a candidate's back pain is probably nerve root irritation suggesting a disc problem. Dr. Brudenell testified the conventional medical method for accomplishing a disc decompression was to "suck out" the disc material through a large needle inserted in the patient's spine. He said VAX-D therapy accomplishes disc decompression by a non-surgical procedure called "distraction." Rather than sucking the disc material out of the patient's body altogether via surgery, VAX-D therapy results in a non-invasive decompression by creating a vacuum in the disc itself which sucks the extruded disc material back into it. This, according to Dr. Brudenell, reduces nerve root irritation. Dr. Brudenell testified that distraction causes a vacuum (reduced intra disc pressure) when the fibrous material surrounding the disc space is stretched. Distraction occurs when there is pulling from opposite directions in a process analogous to a "Chinese finger pull." Traction, on the otherhand, only pulls from one direction and relies on resistance provided by a person's upper body weight being pulled across a surface. Dr. Brudenell testified that the VAX-D therapy also promotes healing of the irritated nerve root by enlarging the "window" (foramen) through which it passes. Specifically, he testified that an irritated nerve root can be compared to a swollen "cork in the neck of a bottle." The VAX-D therapy opens the "window" on a concyclical basis, usually about one minute, approximately 15 times during a 30-minute session, five days a week for about three weeks. Dr. Brudenell opined that the cumulative effect from enlarging the "window" on a temporary, yet concyclical basis, is healing of the swollen nerve. Morris Horning, M.D., testified that, in his opinion the VAX-D therapeutic table is a "smart idea" because it "eliminates the friction problems" associated with traditional traction, "but basically the effect on the spine is still [the result of] traction." He testified his opinion was based on his review of the professional literature, specifically, an article in the September 1994 Journal of Neurosurgery, referred to in the VAX-D promotional video. Dr. Horning testified that decompression can be accomplished by surgery or traction. He asserted that practitioners in his specialty, rehabilitation medicine, "owe some thanks to the VAX-D people because [conventional] traction with less than 50 pounds is a waste of time." Nevertheless, Dr. Horning testified that "distraction and traction are essentially the same thing" and that increased intradisc pressure can also be obtained by adding more weight to the standard traction unit. Applicant argues that the VAX-D therapy is different than ordinary traction and should not be coded as such. Applicant further argues that because the procedure results in decompression, it should be coded and paid at that fee schedule rate. Alternatively, Applicant argues the VAX-D should be coded as an unspecified physical therapy procedure which would permit it to be paid at reasonable rate. Applicant argues $175.00 per session is reasonable. On the otherhand, Employer argues that because the AMA has assigned VAX-D treatments the CPT code for traction they should not be paid at a rate which exceeds the maximum amount permitted under the fee schedule for traction, $40.68. FINDINGS OF FACT AND CONCLUSIONS OF LAW AS 23.30.095(a) states in pertinent part: The employer shall furnish medical, surgical, and other attendance or treatment, nurse and hospital service, medicine, crutches, and apparatus for the period which the nature of the injury or the process of recovery requires, not exceeding two years from and after the date of injury to the employee. AS 23.30.095(f) provides: All fees and other charges for medical treatment or service shall be subject to regulation by the board but may not exceed usual, customary, and reasonable fees for the treatment or service in the community in which it is rendered, as determined by the board. An employee may not be required to pay a fee or charge for medical treatment or service. Our implementing regulation, 8 AAC 45.082(i), states in pertinent part: Fees for medical treatment are determined as follows: (1) The fee may not exceed the physician's actual fee or the usual, customary, and reasonable fee as determined under this subsection, whichever is lower. (2) The board will publish annually a bulletin for the "Workers' Compensation Manual," published by the department which gives the name and address of the organization whose schedule of providers' charge data must be used in determining the usual, customary, and reasonable fee for medical treatment or services for injuries that occur on or after July 1, 1988. The manual, and the organization's name and address are available upon request from the State of Alaska Workers' Compensation Division, P.P. Box 21149, Juneau, Alaska 99802-1149. (3) The usual, customary, and reasonable fee must be determined based on the 90th percentile of the range of charges for similar services reported to the organization described in (2) of this subsection. The organization charge data must be used as follows: (A) If the organization publishes the schedule of usual, customary, and reasonable fees on a quarterly basis, the publication for the calendar quarter in which the employee received treatment must be used. However, if the organization instead publishes the schedule semi-annually, the semi-annual publication for the period in which the employee received treatment must be used. The usual, customary, and reasonable fee must be based on the schedule in effect at the time the employee received the treatment. (B) If the community in which services were rendered is not included in the organization's data, or if the type of treatment the employee received is not included in the organization's data for the community in which services were rendered, the usual and customary fee must be based on the data reported for the community nearest to the community in which the services were rendered to the employee. (C) If the type of treatment or service the employee received is not included in the organization's data and the employer has evidence that the fee exceeds the usual, customary, and reasonable fee charged in the community for the treatment or services rendered, the employer shall pay the physician based on the employer's evidence. In accordance with AS 23.30.110 and 8 AAC 45.070, the physician may request a hearing for a board determination of the usual, customary, and reasonable fee in the community for the treatment or service, and board will determine and award the usual, customary, and reasonable fee. In Abel v. Spenard Builders Supply, AWCB Decision No. 97-0098 (April 24, 1997), we stated: AS 23.30.095 empowers us to authorize and regulate the payment of medical treatment, and to determine the cost of that treatment. As noted, we have appointed Medicode to provide the "schedule of providers' charge data," i.e., the fee for a given treatment or service. We find Employer does not dispute the efficacy or frequency of the VAX-D treatments in this claim; nor does Employer dispute whether Employee's treatment is reasonable and necessary to his course of recovery. We find Employer only disputes the amount Applicant charged for such treatment. Therefore, to resolve this dispute we must first determine whether the service provided is covered by our fee schedule. We find it is not. First, we find the VAX-D therapeutic table is new treatment modality which, although similar, is not a traction unit and therefore should not be assigned the CPT code for traction. We make this finding based on the testimony of Dr. Brudenell who explained the difference between distraction and traction. Specifically, Dr. Brudenell testified that distraction is opposite forces pulling against each other while traction relies on the resistance provided by a patient's body being pulled over a surface in one direction only. We find Dr. Horning corroborated Dr. Brudenell's position in this respect when he testified that the VAX-D table is a "smart idea" because it eliminates "friction problems." For these reasons, we do not adopt the AMA's June 3, 1996 categorization of VAX-D therapy as traction with CPT code 97012. Second, we also find, based on Dr. Brudenell's testimony, that VAX-D treatments are non-invasive. Therefore, we conclude such treatments cannot be coded as a surgical procedure (64722), even though the therapeutic result is the same as for a surgical decompression. Finally, we find the CPT code 97799 for "unlisted physical medicine/ rehabilitation services/ procedures" is also inapplicable because such classification is for "procedures too variable to set a relative value." We base this finding on the testimony of Dr. Brudenell, Mr. Schalow, and Physical Therapist Ratliff that the VAX-D treatments are similar in nature (30 minutes per day, five days per week for approximately three weeks) and are charged at a standard rate of $175.00 per session. Based on these findings, we conclude there is no appropriate CPT code for VAX-D therapy. Accordingly, we conclude that the "type of treatment" Employee "received is not included in the organization's [Medicode] data." 8 AAC 45.082(i)(3)(C). Consequently, we must now determine the "usual, customary, and reasonable fee in the community" for the treatment. We find, based on Mr. Schalow's testimony, that Applicant is the only facility in Alaska to provide this particular treatment modality. We find, again based on Mr. Schalow's testimony, that VAX-D treatments are charged at between $175.00 and $220.00 per session in other areas of the United States. Based on this testimony, we conclude $175.00 per session is the usual, customary and reasonable charge for this modality in Alaska, at this time. Accordingly, we will order Employer to pay Applicant for the VAX-D treatments it provided to Employee, to the extent such treatments were delivered in accordance with AS 23.30.095(c), at the rate of $175.00 per session, less any amounts Employer has already paid for such service. ORDER Employer shall pay Applicant at the rate of $175.00 per session, in compliance with AS 23.30.095(c), less any amounts already paid, for VAX-D treatments provided to Employee. Dated at Anchorage, Alaska this 28th day of August, 1997. ALASKA WORKERS' COMPENSATION BOARD /s/ Rhonda L. Reinhold Rhonda Reinhold, Designated Chairman /s/ John A. Abshire John A. Abshire, Member /s/ Marc D. Stemp Marc D. Stemp, Member If compensation is payable under terms of this decision, it is due on the date of issue and penalty of 25 percent will accrue if not paid within 14 days of the due date unless an interlocutory order staying payment is obtained in Superior Court. APPEAL PROCEDURES This compensation order is a final decision. It becomes effective when filed in the office of the Board unless proceedings to appeal it are instituted. Proceedings to appeal must be instituted in Superior Court within 30 days of the filing of this decision and be brought by a party in interest against the Board and all other parties to the proceedings before the Board, as provided in the Rules of Appellate Procedure of the State of Alaska. RECONSIDERATION A party may ask the Board to reconsider this decision by filing a petition for reconsideration under AS 44.62.540 and in accordance with 8 AAC 45.050. The petition requesting reconsideration must be filed with the Board within 15 days after delivery or mailing of this decision. MODIFICATION Within one year after the rejection of a claim or within one year after the last payment of benefits under AS 23.30.180, 23.30.185, 23.30.190, 23.30.200 or 23.30.215 a party may ask the Board to modify this decision under AS 23.30.130 by filing a petition in accordance with 8 AAC 45.150 and 8 AAC 45.050. CERTIFICATION I hereby certify that the foregoing is a full, true and correct copy of the Decision and Order in the matter of Buddy North, employee / Alaska Physical Therapy & Rehabilitation, applicant; v. Anchorage School District, employer (self-insured) / defendant; Case No. 9619092; dated and filed in the office of the Alaska Workers' Compensation Board in Anchorage, Alaska, this 28th day of August, 1997. Trisha Bruesch, Clerk SNO The AMA develops CPT codes to provide a system for billing similar procedures uniformly to insurance companies and public agencies. The Alaska Workers' Compensation Board appointed Medicode, Incorporated (Medicode) to develop a schedule of providers' charge data which "must be used in determining the usual, customary, and reasonable fee for medical treatment or services . . . ." 8 AAC 45.082(i)(2); see, AS 23.30.095(f) and (j). Medicode has developed and published the "fee schedule" for the Board since 1995. At the Board's direction, Medicode completed extensive revisions to the 1995 fee schedule in 1996. The current fee schedule became effective September 16, 1996, and was updated on March 22, 1997. Because VAX-D therapy involves continuing and multiple treatments of a similar nature, AS 23.30.095(c) is applicable. However, because the parties did not submit this issue for our review, we do not make a determination, at this time.  BUDDY H. NORTH v. ANCHORAGE SCHOOL DISTRICT   page \* arabic2 $%-./2b 4@CF~3J$?$d11::>>@1@`@@@@AACCDDF#FGͻٱj0J@OJQJU>*@OJQJ @OJQJ5@CJOJQJ5@CJ$OJQJ"j5@CJOJQJU5@CJ$OJQJj5@CJ$OJQJU5CJ$OJQJjOJQJUhmHnH4$012bcdefg|+Nqz$*$ 0 $*$0 0$*$$*$GKKKKK   }~ PRz$*$0x 0 $*$ H$*$ H$*$ 0 $*$0 0zd!$$B$m$%%%%''d''8(Y*^+a-._1`11$*$` 0$*$0 0$*$ H$*$ 012{47:<>>>??@@3@G@]@^@@@@@@@@A $*$ $*$ H$*$ 0$*$0x 0AAABCCCDDDFF$FGGGG\HJKKKKKKKd $*$ 0$*$ H $*$ GGG\HaHbHqItIJJJKKKKKKKKKKKKKKKKKKKKKKᱦ @OJQJ@OJQJmHnHj@OJQJUCJ jQCJUjUhmHnHCJ jU>*@OJQJ @OJQJj0J@OJQJU0J@H*OJQJ KKKKKKKKKKKKKKKKKKK $*$  H$$*$ 0dd $*$dh 000P/ =!"#$%....()()))()() 000P/ =!"#$8%8....()()))()()QD phoenixDdw@@0  # Absoeҟl1:;OnGoeҟl1:;PNG  IHDRɉʹgAMAPLTEٟ pHYs&s&slu IDATx]%W^Ouu:5,5e!0a;]FPGm 냳3Ubie;OBawhA1afn!]SnY325so}9?u|G"CCCCCCCC_B^pYܖM ŠgDVbV0s:.Ifhڠp1.Efl1.M;JF|PQb.lM;%_$VK=kSW ͣ:!_kzC!ho`?@FPܯߐkBK #\E5ȟ Ѣs9߿}QaFfmJ}aQ hV@PchR6 zF}'4,W~h~'HCC '~L%[ G7gW)~)h H~ձ> bRr^P#2 MtTzA#j^%g;R>e~.zu}F|˂\]<ů|@-]p EHP5@#(uBR"|٪N?H $( aeTjhjIJ_ƥQjT*A5kPjhd  4Υ=:` - ceC4. *xf!.?7=VaggT^n)jԹВJ4h)t6ԹЬ$-u TCBg~:\hRv(7w@m4Os]b4/\΃feY͇RSy}C}YsEYU9]hےqULKt=.HV;ᇀ־6Bݑz4춤nhTg@B+`hJSRmI\4@Ir e'@(?-@O=y:iizwd=|.%1ӜfnDNg}̷è@ srG@≺%~Qg@S唌IE#MS у(Kr`h) qPjo }>$e((-^M0tʓ*8b4ԓ4Fޓݖe;*C!j736@b][ݱ6[TP>&RP|ly,2D;v@َf<(uXR:3k^3#cx(ztuGdd2Cs!Ul<: 4lrS#Dn)hkm&zfd|ڴr.KvuQ@&_َfmP6.4 ӾKMPeWnٔ%/6(cSM1Y>-!:!Z[l-P>MԌiEYkhj bZ̷ j@`P-*pېoi1QK:' U/F7g,-Pnc[CC Ax1%Q*0ԕc|^bP5E"2/f(ĵU|YK;BTrPK,(PTAҭPRmLW\P4CS (^Я1WN{}V#ƉtMt|½4KzASyOVvw"rf{sojRb@Ƀr a *he<Vׄ!d«|oD<4Zx%3K>'f`w"Ӓ4L#To,Cu?Ѿ"2^]OSUFҞa [OO oG^FYe_3T)eLGlټVaȥZLc;iŞJDlصB{}(Zk,{P[". : F-S,QM*٩3,W|e-7L#T+Uy/eGJ`e[ÞW8M[8 P,HNŋa)c*A &* hfpHVS[)o@Ѥc^ PK)5.4ASMԡ- o X(9VVjeg d(! ; 2'{ں,B^/O-M[=G}r~_(ƺP-3U >䆫S+bkjUOW{p/1t~yjO-M>e3yŎ\f"=|D$O(}N$k*0 5]3 @ѹy _5zPwϬyW*A 1 Grt ڎMA1W( QlVv &sRI94"5 QP!F%^[ {G2Ȏ.D\gG؄SK7qCtA6B:-vqo1= GhB۹\`bGL.2:&GcN%4D %MlK< _ צxF-WKJSP=:Ngc y3 c,?GZ<9aNR4)0*ɗ{C/=8}vL+[dnDr\KP93|8=1)N{Hqzf4LO>l= ?&JU0F?"h=:ԡLŜ.z$M`X|@5ۅFztCyފ3@aLskG[:MI?% +Ժ:4QK1Ro ȃַ U[zDXt`h$jG$54P:WÖw.wti,<#TiC&~TBD[ 4 (PʙP*)lO.Oո=lI d[z}Ɠ9rO)/Fqr;}"]zgS˨SU滗|WBt~^:9[ΪXW}z:±OR kš?C_ Htx&aAQuag9A&:K~Ʈή 4ᘽQB9ZIe_~K>!]s.q!N؏6]H;t(} Cى w (Oә_:e 6>W ~?`7ꧧ%k)N/܌OB >ɵejnWIͪPzc[[7AӋoJg;e Ý~+Pt;n)ջ*6fNs]Z<Ni,]3=^^vEa9cԑt.CMɘFTBm"4=x=/viԙ]cy"ߡ:fW 4-ceP/.vtSࢗݽhi+i8uqRT~k8YE `ٟU.\Os_qֶBAǤf(jU-7s5y=nn58Z@n:[Q5$U|" z:nz\5OJze= Y&žVSMOܽK=zF[7rqd_3 gR(nJ8h.rOfU഼yRy"*:@TM;<" hup_3CX38* [Fc;yDt(V=LJ +EaPRv 览d♩yM3o%\\%nfI55+Cɗ"< N:{2旤T>n>m__DI24U KBz =eyfeb㸮YbK[@4\heTQ:vkUY'@_F. H)BVMzq[)X bCS0Q+;*Vgs{ι.)w|w9ci-_T-G3-bݔN.I>q`@.Ezoo, T~yF-ǃ!>UÕb)cġ[MNkV,w#JeԐ-B7M56E0 T:;-fR1cj;h Y!$>.Ao߯˺ Ǽ}ꛂfY-D{Wʖ%msYar})Q[W%ֶy T#ysɴ4]I(|nM3MQ{XJBEvg\DY#y U4IWz*fTJ$HsT3*fɗTw0?N6YT"qe%nV ˣ.i&qᦠi A=6i˿v[>I>4J9LSTs$A4Cͬ,3&8;~QF!#sZ/~To([P3\Qʃ҇le2Gj&ќP~\M ;Fw]PgAw P=ah=sxjQ|`Z0) Un9l[Fv]3x>"Kj^$~tU}\TmaWһUM*S&$8a"x{Wq}$ 3*Nk#PJ}rt IDATЕT 3p<']xͫ¦Bz43.6ȒBQ?h8qo-W!3BH06 ;9U֝@M\;Ev-\2]`:HTPT7rf(ʰUX_~%*Q!(x=pZ?Jd_g7m9P ᛂv0F+( HpT 9vhPr.0uXə@E$Y7D@Eʷ]SUR-J$vHT= >A`O i7̬tWa?#JsId 4(b='_`~n޴~(vtE)sFAwB5"zyOW~Rqmf!B7;h)O.;rA3>oCuߚZ\b#܋ٓnFr59bA(TT{ĄqR46u3 D4EӪXN^,?8rrbAM*BIk5c^AKvI6 %~zS`WV! ݍ2o͡"gnic*raru\4¯b8jWvmנ/ 8)t@T/ ßo{ :: @}VhRdGG!!fD$li,|[)N2fdmead()#j 1o; ?O.%mbw5wUTr@ e8iJ П8z9wʭҵU! aEd?iPY*URMx&0׾Ӻ=D7}e7(qq b[dmU;> xGݪ@&tr6u [2dW`}9fbYSUNY}j@zSwA"àt)I zS>Y9w-sͮ!(Mu ճx/*A oTAXm? J́&F 8?~>qLt% KU + Ԕ@@[34q%"ڠ|avh,c XFOLi_\ `g G=rMAJ~(k.E}?+MSDT(nȓ`8U::k $AP .+Hp#AS3#Aw|\Q%B g]dP)hlH~UuK PZpaIR6x ;Cw7t^<Ƒ](kPԂϥ6%3/*¡ lv z¬A!,1i-1^5]%_RV {C[IZ/죩jf7$gDKLH.WDJuȃ"2hy yݧP=y/;*[x Eʝ9ϲ.@I/8~kZjI߀+|lxZst ٮ{W <|+o"Gš(VNTb %5<m9T>2hy5\<'|[wtxxŪSlT<0( jWP6_FE!~=̤ۢ UPh w@^^n2;5^Pv/h)J݆G4BKmPPR]>qQVه^82xր0CM^4P4G ==m{( Oߵ]81&~7u p_jgTaU(}/-ϣ?Qןf\p3B\p@"dkבƫTI!j8<,>tFAi2F*:Njo<HU.8J3K@Ió0L#[xGЖ(xd@<>.+V׷ޞjI8ǀ=xㆪ (LZUIiT>YdMbFڨ=6v?/Zmwΐ9\. T[ٌgC+մF#Z@Ƣ"QDo-^\.>G k]rp 8XwI~zH \P_VόZD%p_s ?_gq?shҏi,&O=7IYx=`ߋ}}OQ=>'-!a7tɏkT/ֳ } i:JB_O.ִP] %*eCסZ?T.C{4&PB4.a* zCMbR/!T1ނ]w%9Б= Ca?O?,F&=Ū:~>z._6Pu@4jEx06@"QxjNMAqO,xʞ}~J^4x1JЍ,h1- >A]c'Eg=Q5~fXk.⊱"(5*☺cAGHex U.K6ܨSA=qґkK k ',΅ (} .W j#s +HI_^ uj׍Y y=Lt 0 2;Sڄ䴈db^| gCksXdG-J6nZ]"872B& g4pŷDw&CѰGYn4`:-"_j^$6&JOBLy3S4`á 0Y( AWنb\0o}; eDm+%hip{zzA=X6Ec3U00.à8h^ջ[wpC(P2ހ+&U~Ɩz^HH%d=-Z0xk, `ŰL;zfZ?F=󝃺-k^2T~sodoNBTZ 0ӂy*6u%`#_g /^CW)BFy{?ô36η'$SV3۠>$yd7ت`cOeV9oK==jL<ԄGe7>jp3>Xrܫ^bԷ3>ǘ N,CЯ=gml :Y(lӱlF;*ByϾtZm/eFjM:Ԅ&g&jk]e|ʞ/82'1qP3)O`H 6wKK}Z=`jA!^Zقv!̊sP n:ȡ&<= 8/Iqgx*Ы]yZвS0%,ڀRmekeI# z{ւcI8(V|+WAV2& JiW\Yb-c>grlơqw3PG=: eUqfOΫ(HL^=çMPHIvKS_cɡ3LjAڔqkBU:3]v]0} s 95N6l=5h>TcnR+NSpܓFw=cnx[ԙP@o./maC?P@qsh>\1%l1hcWSԐΑa>t??;_&-gD沷{}3H~a@i V)k _f%NTpIAGM'.A~+,*Ec\!$ Ҩ"<S)P77za}㋯G-\݋JG)vxxDQޑ=2T58f%$dҬ^Y}b dV+aOzoݽ>&^^3yR*jx5T}LןՔj?vfq8#7)9Ŏ_gZLoMaDC}+zއ|?w?9jRDۂV䊭J(˕PeJB>f}^Kx+fv/~, ޿UX*sc_րhGr ҲwakNc^#5Mz>Zo=]gNgF|qJ݃s|cBT@7zc;]ۊ5O!GL$4ZK!W-N6 }@E*exM (_Ph^Ql:+ݱr߭Ceh !r/xo Tm.9Ne܈uXžGѫyR(K|&DVK('a (ԧL)ՀV*ֻ`#=ɥ%vc B[@c)?R \ &P` YF#Տ̷=+~3ɯ5&-Z֊+/DPzӭCPC@eP*fxvІC,kR Rܯ2tבMYCH V]XVR)fn|!'[gTxT ̷pPb` f(j1 𖠰xizq [hhN2Q҄a͠h"ghUGnp 6vr=]zH=n>UlԒ~z7_]u<̺* E/D v$EIXa N,-ElVoMZsR{;޼/&k II-z1GI͈Ɂˁ*b^\PJ MYVyħU }fwsʞD )I2GY6!5c?}=#|g\H<Λ7mʹ^3AՀ͖q{X)|o.Ǧn/?x>/<"`ۆg( <(s"t;(͔T%ʩxy kPsV0 +:n2mX16Z#۲u62{z$BfbF (ugXm*N1yM~C"Yϖߖ|V͹,DuxO `z 4[PQR- plߥؗc(YZ_K@G۠U~ۯ`" -(Z\>KCfCg"QrɢZi3z=ݠv,?K' Mn>9P1M ykw~=vizs OM=PZgTv0["/R)<۠vPR;{&XrW?yͣ*FPTdeCT(' l}OOϦv}T{[#n5浂]0:4TN@,sQn*G~r7+gr#"MRirWQJB=y5N.ZRlS։5šקEv+bA^a%Ikp7 a3 рp4ꇡ#TH'o.F CȒJJsr^dvfR܉MQ i &fD <{-`eR'\0~vՌY(t޵Uކo=Si}Xz>@ z}խTks/S6R=k?2Y9 f,- 'Y +v-lC{vYWjdHiaqn⫡ cp&kK5'۴Nsot> C\:C|U"m(=Q|m;~8}Aþ|m+7OR8|LLr^q5o}O_|̤/ʖ^ m t3ȞAmۥ2C%g@X) Sgl$yQ2P|ܴee{I(Xn"4^iMZyoVY5prٶ$1M0Gyߑbppͥ ̃z\y^A[ rpbB)Dz%~;^qv8E}-/]mPI ^I-ya<{Vg:J!?}ϐVbP o5Ɏ|(Z aB6G  C;@?nGf(+cGw}rϴK7ܷk@h˼$nrV&0ehm+· uq_UV~$|D@59tR*O(8l7M| M0yHv":tIz)zSTM3";G.I_ԎOպpuc%,QKT>kVD 7u#ئ^_bGQ+/4aJmT/T;[QXb{Ƶ%.6MܭSG7% ~zv(/^?!=TxF`)ن-1ĦŕYeEDШzBwڪ9MPńA۟ ϣ31l&hc82KtB_=fP(mۂJpK= KǴ Ρ6V?A}Զ{C^BPh ل,N}[t"uڔ|g,ݑx_6/`ސǸ0zyvQY1+ NPj bZm.QdhČt,QGgiafoq\}Ա\_F"ZKo %Q=`@oNF.GeJ*Ў?fOKHnz>s\?U;ԗݦ19?PO3zq8Wyډm''KT/ߩ \ QϏ1'6@:*Aip}_d27M${&:PO/zA59ϴC>DHP~u!#a_ >. xߐQ.>qkAIiFYOdA֦!'8MV tEaM7kSA5 U]ͯv9BhoHM ^!L5F1^{V]wi*FK_Ssp"43rx]drXZ`3ڴm>%狡A6Xw ]&h4%T,^Akc?IV}j~gt&ͮ$:@Bx/FӧjLp ~i1ٯU@XrJAe(BPmC z*{E󡍈Xc蒓8!hp66N5YcAPb)df>-B~Gޥ5ZlxVv؇Y> ݝ;j%g:Emt1w7Tev<3xuWXkɌ'"l9>ljՏ"tCjY%;j9TC;Ey|ys:YξbD=2P顒 ܱs+Uދ;_:SŒ~<z-ՏO`K jW;i8"qIsw)/ q|Mڝu ?1{oΏ]V6J ?=t{];ʓTiw',^ PD2/$xTt\be}6BWUG Jd)=$lÓeTet2G}^z?QrCz(+UF6]pU\`~6ۃ"07cyF+#q_ݛgHSilZ_Juyq"r~K@ĞOR-2lPIihxb* ~TBm%mۈWou4`gqzEG37~e*ЅIIt#w"WoN|cX͜4^]f % *!hɛ Ԗ NSudVgc3ik! _ CRcƪRF܍F-m4%;/黂j;d?y GJ̭#W߭@ 8WԖ[G߷L?4my[7 +k\NRCQ8/{iQIaX隰4&{g0R3< N "K?j%Ł2Ump}BPU182c\'~{̨˗v2;]KɉqolAq H ?̣vʔBTL;Wfm6_O:iYzoZowG-zz NidŷFa]-|8_;tJT +{̸%Wآȡ:*$v^Cy_0ڲ6ٞ~=l Oå!ކo CHBm*K呧:R֪^9Z1tTK=@p?_~ ne9ڠ?*9ÜbS̚_dh<\Wd(1CH'UFxCE(+2ٳ6JA⅕Ϻ,x\ѝzUK"|Ǥ*<3M: cxu+[݂Zq+Rl"kHu| - UnDFԦ$:;)nVJv*dUʨ )n+GjTf GI$1M0Tm;>X{)hbSr IDo&9C(=;1QQ~ Z'NSgL[^"%Ł¡فuÔc'a 릔AWPTDJm%ubNl&37j&N⯫pA썍hod*7E IDATByw&-9! nX3Mjw̦#WX+BP -P[ aE7|Lif g^-Cߝ5fd2]¦")ff[U"!C%cN6@\*_H-*e󙢵brY/\7w йf9 ҃h,:~F{Z;rDkNт]0K~.Q28ETfV(V5NGd‘FQ7UTNzcW%XW[@Xu'cp1طJץk;Vc5Uf) ńN4EcukclR|Aλ#utDSCqr3\)qM1sJ=6O!ZgS mqAC%(Q'Hγm,lipAJk}WEp:%U>H5Z6K7 g %hF@m\pikvؤBʴ(;P3Z` hC{yS2)Xx5"XQ+{zVNuDDn1m=ϴVh)ζ8ǰ#ۃxKiˆ(S뷦@S5e,䧙&J |m>L5],Ey T% {&2J~SUZóHwH]̗BMDyvAwl9oAICw! ]]g)%P9`pDs;HCm5LODL)[֨84,-DTo_LٗꇘǤIg)<9x 'Լ®N*uLg8>, ħ}XV+fxYbr''V0\YqcmG:|)"ur5-j{4JܺV0h%7%vܙT:"A-rfMz6gA09ųӺ }$ jŰF>)//~bc\m^Q{ UY=u5^SC7zR-~|6X\,d~Jϣl:k-9, YPJ1זcR)VD$ EopM(ZٝJ:6ϸjILwIlezs:? [)QaC†9'=> 2es!@CA37.w{W2ŸȉˣsH}w`SFQEF\i|QODRATmn>%ͣ YŎLWZRQtIdsP`?fὥ&-a#/uQ1|̈́-&u:#]/9BI-yp֙% )5]pޙ5QFF+J: ޘtdh¤9ȡ|^̢֮PY'OOعq?Rtsd„}BwʼmflfuND73Հ& %Iy}`lc  J] '$_Jt$2tSCL# CP,YW%/Wa2((dhl5>1 gk񥔳 O84 i2'rU!h_\D OҤzΥYL )̈́0366fmq7> )oQ{ld!EUp<] HI{؅Nw~Z$8K-+8p_R7GO;|Hă=՚g0"S=7(xIC# j›Џ6+ŷ9E@ᮞF^d_Χhr,{li@?Fa ?j?K 9+@{L?Hkº۝:_  ,J]GI4.`h<c k2u5nHH֞f" ucW${$7I'QPWwl_^EE~+j:@q4S;NxtbV7* Dy.OIt$'j}(P5` ڡ\.G^ih8idQ sgc~Ő^*J+dP{hC˯ UجՂvP[Dɑ"oӴ\6b*@GDc6(o)ReRJ&)%drYn/C`ɒ|cMTn.wWC%#\*J?ȉ;@N4u u!fFn 0I?C4Z6B(Rvc#H4i@K:Wָpv 1aqVd( ۺyg6?پ-|m+-)9FĩmͮPձ#^/phmӻLT8(:fP\e{SWFbʴu^ݪ*Xlg<ɮjCdY;t݋oQy]ْL? ukbr +HphCw;&je쇡b&0+& D`ϣfFJ"iIu)d*WMW>B9$Vgi|'i'O>@Mi]ڙ瘜sО*)|-_LM q"vWZNgEZף:05tߋ' 1-ڴKbW>rT%F=ZЬR/P7PG!t;LS_rz>1kDM2yW䏲 By{v)!q¬yP{Cq}?~;^ߞV普yQ \ xthzyٳGiz5"($YvM2{nIR*r?IJPy!4=+vRpz@u*y=C?+'B7;i + e4(EJP.KjFCRyL*vRo7)Frt[s6= } 3DìFM; 苙,t(URJdMRϫ.Xq^czk_iC\T-B3;j4k%+(>HzsO3[ H26 +l r{=QҴAgkf[8ITO<$&F1y xu5D۽2A%_2:B\TDOsƿ">ͭgO' ױxh҃UZjIBPF{ϯnm\^&>T3C o>@6p6ܦ1WhHJn߈/,Õtb`LqH;_|a1b"YRkQ .v)w&_]榡#&w 1?QQ>iYo+0މn5tȤEi.ĴpCm@KsnYXJZC6܄(슶lԮ?/U}'(*bv!Uˁ)T<9%e)HKW',Vbxl|@ԀPTtMqɐ):/@c ;&wp{5BIxBynK%^yQ'QCf)({/Ρ0w6nk~sP;IР%irOO>U|N8_Rd#0x@qbq[3YQَvK_=/j,(_Eyϻ8dm*_WwJlzB ~ʜ'- @iUJVm>gš$JWVJO| QhghlGLFhExa6ic \, (ߒS1_ۉx̺/ɇNމi D2RFuƄ'&^RQ"`uZձѳ׻2Ȉv&WyLFӥl!\ht̊ckZ x~z xE>$D ?>e%Hj3~b8%DPMq*l=8~4t"4ݝ5U|>d'ag@hޢAO;29۶AiwG?Ow8jE*s]kUVϷBJJ]_/2>!{!HY+ȋn* $_{F]^@@;H[lG49 `+i*$(*-%okӨ%&Fg=)v VzŠ#6x jS1xgC|B.ur#tza4cg{nzğT\ iv+YRqk3?~jԝ& LzR qSOb_/;8* (`4Y(}ߦ#1A MyfdVjE؋>?JH>d іB(o<N<+ETqOy3لQL 429xd 7?=% ݅':QWMЈL)g5Dgn =NdpjZՏ8jW/ɞR"^L-Ay+c,*1tqԣ 1{ ׄʷD)hUQhvpC1iX>9dq Z@jJg}[{1A0v4)W:iMlϪvL&iqEGQIi-OŶ4T>TzNSĺwԕ닰Gk(% wJ X,_`6 bezU.Y0nRe_$* Eu$+~xYv#2N9^_BÀf37it7Kjn4#vЁ-%I<1hOjQIMe:3{ep9ӓWGUw]@6C˚_RT*lWG!\ #,;ۭbv%]$ul/ ;e4fo+7\_l0S6XBJ/Y ^T 1VYF鿁YzC_y4qd̿[c9qxʢzI]+¡% qڡF O+u]q y=KKeZ'_.=ִYnfBϫq(̇bm0oͲl;iIEaJrțz!kE Vwi: oC7礅,[_~2YYhĸ`|;|b"bB9Xj>LIwdUe此D4PO!I#1ګyoY+}u 1<[!;E.,8;H]JXhBqJe[ޱ~^4+ u}M]Zg[ޜ&C^0AhB(JE˜uqG&Чh _mv{抮GSI94lm TvJ6Ak׆ٹkJ.v<^oHCj79*{$cxn~PNCͰ!&%{%Em^RzfLzdR5]$l7[SuV3򛦟ۋUD@J”6\2d,iǶ}u/^ <;K)æ.~OwOw1 W7ZAlBaʊKJ'ҺjIʭZIXR|XopE_ur풭Eհ}qrXev rq L `&,҈̭س3".ӝO,8$jp1k]FZ%7nՕ/Zff?\\}[~˗/_őGn>V`MSA@'ghB+C1KӐDUJ}==m)γ$k}7q;gh*3!gxHYㅰTCH&c|GsPj4VcaL$ΟuVx"&n\Øv*C)҅fi;m@)MJ鄀`G.r|2=GIr&Z"@+TsyOjC*vtAC!DłVCJeJ$s uYy$kc64%/$I_!u!EO!'Ci ŘU L t|cjlBz#XwvAr_$m$ɅZ}ϧO@Us{ r)tOMt7/ߐ0=W)NzֻJ uCr57}V%m-ĵ,t]N˔ YTJz0 i%Gyn$=I_\h,GkU dq/_bͪv^< 愳AwpHB:{d;WNξ {0xiiH4~8([L8*u7ժ`ΆB=zq 2OGsؼfL±Z\ Ag1-&tsqQHwt w5l"bq^5[z//RwwO+MW:D$qv{tl6{*ZFZLNhA P &{iW!Ǡ+cMh6iTer=P]dwЂt&Pf(*i#1"3š:,;>:3bZ6?ɊCCzJophD3p# .FA;77$/qzũ;d;A{iEٍ0̀oЋ:f:p=Nш?y m 5i38gr1g&,EMؿAϳw'Q CACha.88TC45S ߸|=aғH8+?uj;!GU6H)+ܱUEJ~'fTm~{Wy^ΪAs5!ʔs60]eo!jƧ#_P&-tPhAlB&y6#]ntn r>oUz1þ8.hG yhPh-񠟺|[.bc7HmdڭXӱħk(U5 +\J|;=Ŷ?58z.Xڱ9̤{jmB,&Tj5ПMV*nKOߛ r&)Wp4Fgв oՠ/&9\M@5xǗiU(uTO==;f렬],f3USFO6EFJ@uUl5(gBOV]tJJumJ@e=Ƨ l~B!7CG=x${q=uϊ}j묃w ӹ6B XjQ`RjvA.;XQC'ޖi93W2YX綿dP$1`m@Ɨ2XC:_}0jɸY˃ .k/%Zb?=-(DgI'.  BϚ F~b2kmʗRf|<*AU8) @@1;%I0%*A;^e %ebQ`PF|ן78ps;\.hbPri>k;bsr#XY+ꅭET\ USV|у'yMqwG 1 (Xi[dZC"]n ~>Q8as vA+ ~-zUPJvZ=ʛ7ga{ A߁X)9gcRt/zЀ# 7Om4;fcҊnA Z j. $ vsh@ej#AsN6J\q@ uex|Q]@>Ӌy{! ujR2.&ucc:ҧeMP)3浃 #olAXY@PTʡ=7bJs9^sc}1Bvc=teܷgŴj5 ۅW$#qW ?l5fw|vvn.Hw)z[q0>.K;9|ߠSoF6ҠON)so\RgBbl9Gd.e5fݬћi%_01uZ¾k}$O;|4WCbׂ!hP(=ilZ/" oSM ) ~v9ˡ1,}t{ꉝGzqQ+x7YgDG5bZj ւp~3vοΔ6J܋ь_7q _SbTH!hCGזl lvss/J|׏Bn'!H/`-v(L4|*m4ŭ}72;0anqo$B_4'rީQ ^LB>cuXqC;O*/(0QYkWr&z^ܩ+[FI&,dS*~Ty0`}$ 0jbLQtw!Mg俱􊢙TNhsXYajࡎt 0߻b~^-˂U5N57 2J@~3uuێ1Mlzhh<0a[1e5{nL[~R$&!˚2к"$7U w|01&$KB̌|o*gH=0(6^ 5!JH7AOْf?}7] im' QX7CytOs3"ջ KUtf(5!D>浗ߏILI)>IɉH>&Rwӑi_]i'&kG +<*Cfֶ uސ6nw? 켻.^<+$C"A\sqD$wqa$}jxuC=4>au܎P=_}5چ "U%ĜD únugG+$  3jQMst<ѣӠء~P' B‡$,N UAE$3F3a`y {7 o:(=)wQE6։i#,ܞ߀{vi-lxz_yۂsz$Slɑօ7Bw>p/{;ȆF-jkkŊ8V`o) 5蕓k#1L+  nr/|ڀcRT -ص%L2hd?.P(Ho+)uChXPKpGh EW_1 Dy#5]M^'wveY:+֝]ꡡ BAɜݨ"6`S-j5=ʦ"k_Xjc3ɰ>Fp`֞pEY+pSibZokH;Ԓ>B"]OpBÂZ&`_ 9 z1/2.4-ou7\C?[ٳ~~{^LB<<ڵЅjr*K-A1"u?~n6ھ>ϸ@^4k>cN,~Q koAl%xk7B} P0N&.g:}qYSY:375FP}$b~f|&׬TP4z2͠1PMhMPg8|=¼ؓbϢL 'vS/hT&^N}ftShMijbNt LCAjT^:n MjJ9ԍ]9d~dJ?`A|啹 嚠 =xo);b#1;EaAjp>ԛ&]sl+l&#kuŧǻ`-3XbC:7SHk02v2sѕC56POuxʕ ͠"|'"ϯW &POIsc][.4 ns`:J!bxdE#i YJ7Yy0RO7|k3rDXlIXbC=1k Zf0ȥuQaa6?oRju})$6xY]ՂIDATA% g5P>-ffSIyk[Uj n -Iu{Y{ND6^PnlLlռ]8Vm 嚬/ KA5Qk( {*⸪Y luU P3:= ɸPUJp A"LѪ czq} h4lJS$ƏGiqm)݂/-|\[kin以>Z *:=(;D^.U4AP AY1Aͪf̷>q-E B-T>K疠A V* Sa(Uб>YUZ*F(_KSo&ND.ڵ7KTBGKB낷FKAiQ(,'P#$gT(FnڡQ Ѕp66]Qz $KsIhQm<8T8n`-z}MGy's )mEwAH;h>nImwgPX- 垤e**w^IۀFZ!ђRKj֎ׂz5Gm@:tѝ:s/j}+{סA ?1YR7`Ѻppp-h00TsyB[ZыbV]d;Mw]7'cV~\bI1[C{Вcl49׍ºͣvu c;ZZ SȮyPteݙ) 5ې6RCsLҝy8mn{,?rٶnPZ|tJ^ 5aV;-xkC`څ:մN 2vZګ6ꮿ6AyUÐ-mZ_j.S%:݃WBKUYAʬTՖ ZT*GB6ԬkPM6eAK;:2Qq^ivۆھ3~t jIL(| kNVNc i]viZс[W@5.j%6!4g@hQ2;[=Q{*pPEW[<зbiV4,- ʋcL(wh[/jBc0Ս uHû[]&Tx;Л܁AgtxM* \2-@9G3ʗ\> @bi[, V)~P;\n ՅTǁ u(շ[݇ ] 2tvz[IENDB`# [<@<Normal1$CJOJQJhmH nH <A@<Default Paragraph Font,+@, Endnote Text6*@6Endnote ReferenceH*.@. Footnote Text8&@!8Footnote ReferenceH*0O10headingsCJOJQJmH 4OA4 medheadingCJOJQJmH :@:TOC 1*$0 $ 6@6TOC 2*$0 $ 6@6TOC 3*$p0 $ 6@6TOC 4*$@ 0 $ 6@6TOC 5*$0 $ 2@2TOC 6*$0 $*@*TOC 7 *$02@2TOC 8*$0 $2@2TOC 9*$0 $ : @:Index 1*$` $ : @:Index 2*$0 $ 6.@6 TOA Heading *$ $""@"Caption!2O!2_Equation Caption 6GGG G"   G 99>>>AGKJQz1AKKKMNOPRKLG!@ @ (   x  <?  B S  ?(   r  6? GAh@;A0*sGGGGGGGGn/an/a&D:\targetdir\workcomp\1997\97-0182.doc@\\DOL_JNU_NT1\J_CALL6Ne01:winspoolHP LaserJet 5\\DOL_JNU_NT1\J_CALL6psXXLetter 7 6''''\\DOL_JNU_NT1\J_CALL6psXXLetter 7 6''''C Gp@gTimes New RomanTimes New Roman5Symbol?& ArialArialO1CourierCourier NewoNewCenturySchlbkCentury Schoolbook")("("v 7Q$ ;T5)@B]F$97-0182pdq form"position description questionnairen/an/an/an/aOh+'0 $0 L X dpx97-0182 pdq form n/an/am#position description questionnairesosiNormalnn/an/an2anMicrosoft Word 8.0n@@/Q@/Qv 7՜.+,D՜.+,l( px   SOA-L&WDd$QB1 *position description questionnaire [FORM] Title 6> _PID_GUIDAN{B215F8F6-6214-11D3-8867-00A0C956CDB1}  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~Root Entry]+H` F@gfp@b=QData UH1TableWordDocument SummaryInformation(DocumentSummaryInformation8CompObjjObjectPoolp@b=Qp@b=Q  FMicrosoft Word Document MSWordDocWord.Document.89q